SRC and Alzheimer disease: This interest led to a phase Ib clinical trial (NCT01864655) to assess the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib), an inhibitor of Src and Abl family kinases1 with a high potency for Src and Fyn in mild to moderate AD patients [50].